Single peptide Vial strength 5 mg
CJC-1295 DAC5 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
CJC-1295 DAC, explained simply
A longer-acting GHRH analogue. Its DAC modification distinguishes it from the shorter-acting version.
Research area
GH/IGF-1 axis
How it works
Binds pituitary GHRH receptors; the DAC modification supports albumin binding and a longer time in circulation.
Why it matters
It is studied for the duration of GH and IGF-1 responses and related metabolic processes.
What has been observed
Human studies show increases in GH and IGF-1 following CJC-1295 DAC administration.
Effects and points to consider
A measured hormonal response does not automatically translate into clinical benefits for body composition or recovery.
01 / Vial strength 5 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 5 mg CJC-1295 DAC |
|---|---|
| Final volume | 2 mL |
| Concentration | 2.5 mg/mL |
| One U-100 unit | 25 mcg in 0.01 mL |
Standard / Gradual Approach (2 mL = 2500 mcg/mL)
| Week | Per-Injection Dose (mcg) | Units (per injection) (mL) | Weekly Total |
|---|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) | 12 units (0.12 mL) | 600 mcg/week |
| Weeks 3–4 | 500 mcg (0.5 mg) | 20 units (0.20 mL) | 1000 mcg/week |
| Weeks 5–6 | 750 mcg (0.75 mg) | 30 units (0.30 mL) | 1500 mcg/week |
| Weeks 7–12 | 1000 mcg (1 mg) | 40 units (0.40 mL) | 2000 mcg/week |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.